Oncology Programs

Developing siRNA therapeutics to treat Familial Adenomatous Polyposis (FAP), bladder cancer and liver cancer.

Marina Biotech is focusing its pipeline efforts on the discovery and development of novel RNAi-based therapeutics for diseases with critical unmet medical needs. Specifically, programs have been established for Familial Adenomatous Polyposis (FAP), and in the area of oncology, bladder cancer and hepatocellular carcinoma (liver cancer).

Oncology Pipeline

Marina Biotech Clinical Pipeline

To specifically inhibit therapeutic targets in these disease states in the most efficient manner, Marina Biotech is using both of its proprietary drug discovery platforms: tkRNAi for FAP and tauRNAi for bladder and liver cancer.

Share Print